Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

• Yan Qiu,
• Chao-Ling Wan,
• Ming-Zhu Xu,
• Hai-Xia Zhou,
• Mei-Jing Liu,
• Wen-Jie Gong,
• Li-Qing Kang,
• Ai-Ning Sun,
• Lei Yu,
• De-Pei Wu,
• Chong-Sheng Qian,
• Sheng-Li Xue

Affiliations

Yan Qiu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Chao-Ling Wan

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Ming-Zhu Xu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Hai-Xia Zhou

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Mei-Jing Liu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Wen-Jie Gong

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Li-Qing Kang

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd

Ai-Ning Sun

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Lei Yu

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd

De-Pei Wu

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Chong-Sheng Qian

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University

Sheng-Li Xue

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University